Hyaluronidase
Enzyme that degrades hyaluronic acid in extracellular matrix — 'spreading factor' enhancing diffusion of other SGS compounds.
- Hementerin80 kDa
- Hementin80 kDa
- Hementin-Like Protein (HLP-1)80 kDa
- Leech Collagenase70 kDa
- Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
- Leech Apyrase67 kDa
- Calin65 kDa
- Hyaluronidase60 kDa
- Antithrombin III binding protein58 kDa
- Collagenolytic Fibrinolysin55 kDa
- Leech Thrombospondin-Like Protein50 kDa
- LHyal (Leech Hyaluronidase)50 kDa
Mechanistic Evidence Box
Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.- Page type
- Compound profile
- Evidence type
- Clinical and regulatory evidence (FDA-approved derived drug)
- Evidence level
- Mechanistic discussion
- Drug vs leech
- Leech-derived crude extract
Clinical translation limit
Leech hyaluronidase is mechanistically related to (but distinct from) the human recombinant hyaluronidase product Hylenex, which is an FDA-approved separate pharmaceutical with its own evidence base. Leech-derived hyaluronidase has no independent FDA approval and its 'spreading factor' role is preclinical/mechanistic only.
Molecular Profile
- Category
- ECM Enzyme
- Evidence tier
- Tier A — FDA-approved derivative
- Molecular weight
- 60,000 Da
- Source species
- Hirudo medicinalis
- Derived FDA-approved drug
- Conceptual relative: human recombinant hyaluronidase (Hylenex)
Biological Targets
- → hyaluronic acid (extracellular matrix)
Key Citations
- Hovingh P, Linker A (1999), Comp Biochem Physiol